About: In silico multi-epitope vaccine against covid19 showing effective interaction with HLA-B*15:03

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: In silico multi-epitope vaccine against covid19 showing effective interaction with HLA-B*15:03 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	In silico multi-epitope vaccine against covid19 showing effective interaction with HLA-B*15:03
Creator	Gupta, Ankit Kumar, Ashwani Abdelazim, Dina Abdelmoneim 5#, Abdelrahman Abdulaziz, Ibrahim Abdullah, Tariq Akram, Fareeha Bhupender, Calderon-Tantalean, Jose Chaudhary, Uma Chimaobi, James Faiza, Muniba Faruque, Fakhrul Gharip, Ali Khalid, Aqsa Kigen, Collins Manikumar, Manne Munawar, Saba Ononamadu, Thakur, Singh Upadhyay, Ravindranath
Source	BioRxiv
abstract	The recent outbreak of severe acute respiratory syndrome (SARS) coronavirus (CoV)-2 (SARS-CoV-2) causing coronavirus disease (covid19) has posed a great threat to human health. Previous outbreaks of SARS-CoV and Middle East respiratory Syndrome CoV (MERS-CoV) from the same CoV family had posed similar threat to human health and economic growth. To date, not even a single drug specific to any of these CoVs has been developed nor any anti-viral vaccine is available for the treatment of diseases caused by CoVs. Subunits present in spike glycoproteins of SARS-CoV and SARS-CoV-2 are involved in binding to human ACE2 Receptor which is the primary method of viral invasion. As it has been observed in the previous studies that there are very minor differences in the spike glycoproteins of SARS-CoV and SARS-CoV-2. SARS-CoV-2 has an additional furin cleavage site that makes it different from SARS-CoV (Walls et al., 2020). In this study, we have analyzed spike glycoproteins of SARS-CoV-2 and SARS-CoV phylogenetically and subjected them to selection pressure analysis. Selection pressure analysis has revealed some important sites in SARS-CoV-2 and SARS-CoV spike glycoproteins that might be involved in their pathogenicity. Further, we have developed a potential multi-epitope vaccine candidate against SARS-CoV-2 by analyzing its interactions with HLA-B*15:03 subtype. This vaccine consists of multiple T-helper (TH) cells, B-cells, and Cytotoxic T-cells (CTL) epitopes joined by linkers and an adjuvant to increase its immunogenicity. Conservation of selected epitopes in SARS, MERS, and human hosts, suggests that the designed vaccine could provide cross-protection. The vaccine is designed in silico by following a reverse vaccinology method acknowledging its antigenicity, immunogenicity, toxicity, and allergenicity. The vaccine candidate that we have designed as a result of this work shows promising result indicating its potential capability of simulating an immune response.
has issue date	2020-06-14(xsd:dateTime)
bibo:doi	10.1101/2020.06.10.143545
has license	biorxiv
sha1sum (hex)	bdad47079700e7b9aae9bf35b79f6f170c1c93eb
schema:url	https://doi.org/10.1101/2020.06.10.143545
resource representing a document's title	In silico multi-epitope vaccine against covid19 showing effective interaction with HLA-B*15:03
schema:publication	bioRxiv
resource representing a document's body	covid:bdad47079700e7b9aae9bf35b79f6f170c1c93eb#body_text
is schema:about of	named entity 'involved' named entity 'ACE2 Receptor' named entity 'binding' named entity 'Further' named entity 'outbreaks' named entity 'B-cells' named entity 'immunogenicity' named entity 'spike' named entity 'Conservation' named entity 'PATHOGENICITY' named entity 'HAVE' named entity 'subtype' named entity 'provide' named entity 'spike' named entity 'SARS-CoV' named entity 'vaccine' named entity 'involved' named entity 'B-cell' named entity 'Immunoglobulin' named entity 'epitopes' named entity 'epitopes' named entity 'anti-viral' named entity 'SARS-CoV' named entity 'caused' named entity 'SARS-CoV' named entity 'selected' named entity 'study' named entity 'SARS-CoV-2' named entity 'HLA-B' named entity 'SARS-CoV-2' named entity 'coronavirus disease' named entity 'vaccine' named entity 'immunogenicity' named entity 'CTL' named entity 'T-helper' named entity 'severe acute respiratory syndrome' named entity 'epitopes' named entity 'epitopes' named entity 'phylogenetically' named entity 'vaccine' named entity 'epitope' named entity 'vaccine' named entity 'protein-protein interaction' named entity 'positively selected' named entity 'vaccine' named entity 'epitope' named entity 'glycoprotein' named entity 'SARS-CoV' named entity 'B-cell' named entity 'allergen' named entity 'vaccination' named entity 'immunogenicity' named entity 'infection' named entity 'β-sheets' named entity 'epitope' named entity 'vaccine' named entity 'toxicity' named entity 'epitope' named entity 'vaccine' named entity 'Antigenic' named entity 'p-value' named entity 'SARS-CoV-2' named entity 'Cytokines' named entity 'epitope'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software